Marco Meglio

Early ASPIRO trial data show autologous stem-cell dopamine precursors stay safe at 12 months, with improved PD motor scores and PET-confirmed grafting.

Two phase 3 ADAGIO trials test Cobenfy for Alzheimer’s agitation, assessing muscarinic modulation safety and efficacy as a potential new dementia care option.

UK platform trial enrolls 1,600 with Parkinson’s to rapidly test telmisartan, terazosin and new candidates via shared placebo and virtual visits.

The division chief of neuroimmunology at Brigham and Women’s Hospital discusses longitudinal EBNA-1 antibody data and its potential role as a complementary biomarker to distinguish MS from related neuroinflammatory diseases.

A global survey of neurologists and psychiatrists found that although tetrabenazine remains widely used for tardive dyskinesia and Huntington disease–related chorea, side effects frequently prevent optimal dose titration and lead to treatment discontinuation.

A post hoc analysis of the AMPA observational study found that adjunctive perampanel did not worsen daytime sleepiness over 12 months in patients with focal epilepsy while maintaining substantial seizure reduction.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is cerebroprotection in stroke!

A randomized trial in patients with CIDP found that adding intravenous methylprednisolone to IVIg did not significantly increase remission rates and was associated with thromboembolic safety concerns.

Phase 3 data show azetukalner cuts monthly focal seizures in refractory epilepsy, offering a novel KV7 option ahead of 2026 FDA filing.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with AAN President Natalia Rost, MD, MPH. [LISTEN TIME: 16 minutes]

A comparative analysis presented at the 2026 MDA Conference suggests the intrathecal gene therapy Itvisma may achieve similar motor outcomes to nusinersen and risdiplam in patients with spinal muscular atrophy.

John Crowley, chief executive officer of the Biotechnology Innovation Organization, discusses the evolving biotechnology ecosystem, emerging therapeutic technologies, and ongoing policy challenges shaping the future of rare disease innovation.

SAFARI44 launches a phase 3 test of del-zota for DMD exon 44 skipping, tracking muscle function and dystrophin gains over 54 weeks.

Phase 2 CANYON data show sevasemten keeps LVEF steady and NT-proBNP stable in adults with Becker muscular dystrophy, hinting at heart protection.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Seronegative generalized myasthenia gravis!

PrimeC shows significant survival gains and slowed progression in ALS phase 2b follow-up, fueling plans for larger late-stage trials.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Amaal Starling, MD, FAHS, FAAN. [LISTEN TIME: 16 minutes]

Pilot trial finds low-dose lithium is safe in mild cognitive impairment, hints at memory benefits, and guides larger studies for Alzheimer prevention.

The associate professor of neurology at Mayo Clinic provided a breakdown of the real-world eptinezumab data from INFUSE and its implications for early, robust migraine intervention after CGRP failure.

Real-world INFUSE results show IV eptinezumab boosts good days and cuts monthly headache days for hard-to-treat migraine patients.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is diagnostic workup for multiple system atrophy!

In honor of Black History Month, neurologist Na Tosha Gatson, MD, PhD, reflects on structural inequities in neuro-oncology and advancing equity through mentorship, trial design, and institutional policy.

Anjail Sharrief, MD, Director of Stroke Prevention for the Institute of Stroke and Cerebrovascular Disease at UTHealth Houston, reflects on Black History Month, structural drivers of stroke inequities, and building systems that advance equitable brain health.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Lauren Sansing, MD, MS, FAHA, FANA. [LISTEN TIME: 27 minutes]

Praxis files FDA NDAs for ulixacaltamide and relutrigine, highlighting phase 3 tremor gains and major seizure cuts in rare DEEs.

Phase 3 data showed efgartigimod improved ocular myasthenia symptoms, paving way for FDA filing and potential first targeted option for patients.

EryDex failed to significantly improve neurologic outcomes compared with placebo in pediatric patients with ataxia-telangiectasia in the phase 3 NEAT trial.

Early ALS trial showed that microbiome gut-brain therapy PLL001 is safe, paving way for 6-month phase 2 study testing efficacy and gut repair.

In this Q&A, migraine expert Deena Kuruvilla, MD, FAAN, provided clinical context on the phase 4 COMPEL trial testing onabotulinumtoxinA as a preventive treatment of chronic migraine in diverse racial groups.

Xenos Mason, MD, a neurologist specializing in movement disorders, provides commentary on an early-stage study evaluating induced pluripotent stem cells for patients with Parkinson disease.